SAHPRA and SAPC Enforcement Highlights Confusion Around Longevity Medicine in South Africa

Like the rest of the world, South Africans want to live longer and healthier lives.

Search interest and consumer conversations around NAD+, peptides, metabolic health, recovery therapies, biohacking and healthy ageing have accelerated sharply in recent years.

Yet as the category grows, many consumers still struggle to understand the difference between evidence-based longevity medicine, wellness marketing, compounded products, supplements and unregistered medicines.

Trust issues

The recent enforcement action by the South African Health Products Regulatory Authority (SAHPRA), in collaboration with the South African Pharmacy Council (SAPC), has brought that confusion into sharp focus.

SAHPRA has announced enforcement action against the unlawful manufacture and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide or a combination of both, promoted for weight-loss purposes.

The regulator confirmed that a joint inspection at a Pretoria-based facility had identified serious regulatory non-compliance, including concerns around manufacturing standards, quality controls, analytical testing, sterile preparation and pharmacovigilance.

While the action centred on weight-loss medicines, NADclinic South Africa believes the implications extend far beyond GLP-1 products.

The incident highlights a broader challenge facing South Africa's emerging longevity sector: trust.

“The biggest challenge facing longevity medicine in South Africa is not demand. It is understanding,” says Dr Henry Davis, resident physician at NADclinic South Africa.

“Consumers are hearing terms like NAD+, peptides, regenerative medicine, metabolic optimisation and biohacking every day.”

“Very few understand how these interventions differ, how they are regulated, or what standards should apply. That is where confusion enters the market.”

Questions of legitimacy

The longevity industry has grown rapidly internationally as healthcare shifts from reactive treatment towards earlier intervention, prevention, health span and performance optimisation.

The speed of that growth has also created a crowded marketplace, with competing claims, influencer-led health advice and products of varying quality, legitimacy and clinical oversight.

For consumers, the lines can quickly become blurred.

“Most people are not clinicians,” says Davis.

“They are trying to make decisions based on information they find online, on social media or through word-of-mouth recommendations.”

“The problem is that many of these conversations blur the line between wellness, medicine and marketing.”

According to Davis, longevity interventions should not be treated as ordinary consumer wellness purchases.

When protocols involve diagnostics, biomarker analysis, IV therapies, prescription medicines, peptides or advanced performance interventions, they become clinical decisions that require qualified oversight.

“Trust has to come before treatment,” he says.

“People should understand where products come from, who is supervising their care, what evidence supports the intervention and whether appropriate diagnostics have been conducted before any protocol is recommended.”

The company says these protocols are used in professional sports settings where product provenance, clinical oversight, documentation and compliance are essential.

“In professional sport, the standard is very clear,” says Davis.

“There can be no grey area around product sourcing, protocol design, medical supervision or anti-doping compliance.”

“That same mindset is increasingly important in consumer longevity medicine.

“The more advanced the intervention, the more important the governance behind it becomes.”

You have 30 minutes

Industry observers believe SAHPRA's recent action may ultimately accelerate the maturation of the local longevity market by forcing both providers and consumers to focus on standards, transparency and accountability.

NADclinic South Africa argues that the future of longevity medicine will be defined less by marketing claims and more by clinical governance, diagnostics, measurable outcomes and legitimate pharmaceutical supply chains.

The timing is significant.

Internationally, demand for preventative healthcare, healthy ageing, recovery medicine and performance optimisation continues to grow.

South Africa is beginning to follow the same trajectory, but NADclinic South Africa believes education will be critical if the sector is to develop responsibly.

“Longevity medicine is still new territory for many South Africans,” says Davis.

“That creates both opportunity and risk.”

The opportunity is that people are becoming more proactive about their health than ever before.

The risk is that misinformation can spread faster than understanding.

As regulators tighten oversight and consumers become more informed, trust may prove to be the defining currency of South Africa's next healthcare frontier.